This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eppes, S. C.
Right arrow Articles by Childs, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eppes, S. C.
Right arrow Articles by Childs, J. A.
Related Collections
Right arrow Infectious Disease & Immunity
Right arrowRelated AAP Red Book topics:
Lyme Disease (Lyme borreliosis,...
Clostridium difficile

PEDIATRICS Vol. 109 No. 6 June 2002, pp. 1173-1177

EXPERIENCE AND REASON

Comparative Study of Cefuroxime Axetil Versus Amoxicillin in Children With Early Lyme Disease

Cefuroxime axetil has been shown to have efficacy comparable to doxycycline in adults with early Lyme disease (LD). Because of toxicity, doxycycline is usually avoided in children. For children who are unable to tolerate amoxicillin, there is currently no proven alternative oral therapy for LD. This randomized, unblinded study compared 2 dosage regimens of cefuroxime axetil (20 mg/kg/d and 30 mg/kg/d) with amoxicillin (50 mg/kg/d), each given for 20 days. Children were enrolled if they were 6 months to 12 years of age, had erythema migrans, and met other eligibility requirements. Serologic testing occurred at entry and after 6 months. Follow-up evaluations for safety, tolerability, and efficacy occurred at 10 and 20 days, 6 months, and 1 year. Forty-three children were randomized (13 in the amoxicillin group, 15 in each cefuroxime axetil group); 39 completed 12 months of follow-up. At the completion of treatment, there was total resolution of erythema migrans in 67% of the amoxicillin group, 92% of the low-dose cefuroxime group, and 87% of the high-dose cefuroxime group, and resolution of constitutional symptoms occurred in 100%, 69%, and 87%, respectively. All patients had a good outcome, with no long-term problems associated with LD. One patient, who was well at the first 2 follow-up visits, was treated with doxycycline because of new constitutional symptoms. Mild diarrhea occurred in a small number of participants in each group (1 patient was diagnosed and treated for Clostridium difficile-associated diarrhea, which occurred after completing the full course of study medication). No hypersensitivity reactions occurred. The number of patients in this trial was not sufficient to demonstrate a statistically significant difference between the 3 groups; however, both amoxicillin and cefuroxime axetil seem to be safe, efficacious treatments for children with early LD.

Stephen C. Eppes, MD*,{ddagger} and Judith A. Childs, PhD*

* Alfred I. DuPont Hospital for Children, Wilmington, DE 19899
{ddagger} Jefferson Medical College, Philadelphia, PA

-->

Key Words: Lyme disease • cefuroxime • antibiotic therapy

Abbreviations: LD, Lyme disease • EM, erythema migrans • MBC, minimum bactericidal concentration

Received for publication Apr 16, 2001; Accepted Feb 21, 2002.




This article has been cited by other articles:


Home page
 JAMAHome page
C. D. Tibbles and J. A. Edlow
Does This Patient Have Erythema Migrans?
JAMA, June 20, 2007; 297(23): 2617 - 2627.
[Abstract] [Full Text] [PDF]

Home page
 Evid. Based Nurs.Home page
OTHER ARTICLES NOTED (Nov 01 to 18 Oct 02)
Evid. Based Nurs., January 1, 2003; 6(1): e1 - 1.
[Full Text] [PDF]

Home page
 JWatch Infect. DiseasesHome page
Oral Cefuroxime vs. Amoxicillin for Children with Early Lyme Disease
Journal Watch Infectious Diseases, July 26, 2002; 2002(726): 17 - 17.
[Full Text]